Analysis of Food and Drug Administration-approved anticancer agents in the NCI60 panel of human tumor cell lines.

@article{Holbeck2010AnalysisOF,
  title={Analysis of Food and Drug Administration-approved anticancer agents in the NCI60 panel of human tumor cell lines.},
  author={Susan L. Holbeck and Jerry M. Collins and James H. Doroshow},
  journal={Molecular cancer therapeutics},
  year={2010},
  volume={9 5},
  pages={
          1451-60
        }
}
Since the early 1990s the Developmental Therapeutics Program of the National Cancer Institute (NCI) has utilized a panel of 60 human tumor cell lines (NCI60) representing 9 tissue types to screen for potential new anticancer agents. To date, about 100,000 compounds and 50,000 natural product extracts have been screened. Early in this program it was discovered that the pattern of growth inhibition in these cell lines was similar for compounds of similar mechanism. The development of the COMPARE… CONTINUE READING
BETA

Citations

Publications citing this paper.
SHOWING 1-10 OF 78 CITATIONS

Synergistic Growth Inhibition by Afatinib and Trametinib in Preclinical Oral Squamous Cell Carcinoma Models

Pei San Yee, Nur Syafinaz Zainal, +7 authors Sok Ching Cheong
  • Targeted Oncology
  • 2019
VIEW 1 EXCERPT
CITES METHODS

FILTER CITATIONS BY YEAR

2010
2019

CITATION STATISTICS

  • 7 Highly Influenced Citations

  • Averaged 10 Citations per year over the last 3 years

Similar Papers

Loading similar papers…